The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Advances in CAR T Therapy for Hematologic Malignancies
Freyer, C. W., & Porter, D. L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2414 · Cited by 21
Rodrigues, J. M., Nikkarinen, A., Hollander, P., Weibull, C. E., Räty, R., Kolstad, A., Amini, R., Porwit‐MacDonald, A., Jerkeman, M., Ek, S., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17366 · Cited by 24
Novel strategies for immuno-oncology breakthroughs with cell therapy
Liu, H., Pan, C.-X., Song, W., Liu, D., Li, Z., & Zheng, L. (2021) · Biomarker Research · doi:10.1186/s40364-021-00316-6 · Cited by 20
Self-citationMansouri, V., Yazdanpanah, N., & Rezaei, N. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1984449 · Cited by 21
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
Munoz, J. L., Wang, Y., Jain, P., & Wang, M. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01286-0 · Cited by 21
Self-citationTumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Saleh, K., Cheminant, M., Chiron, D., Burroni, B., Ribrag, V., & Sarkozy, C. (2022) · Cancers · doi:10.3390/cancers14133229 · Cited by 22
Migratory Engineering of T Cells for Cancer Therapy
Michaelides, S., Obeck, H., Kechur, D., Endres, S., & Kobold, S. (2022) · Vaccines · doi:10.3390/vaccines10111845 · Cited by 21
Epstein‒Barr virus–associated cellular immunotherapy
Zhang, Y., Lyu, H., Guo, R., Cao, X., Feng, J., Jin, X. K., Lu, W., & Zhao, M. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.04.003 · Cited by 21
Lam, N., Finney, R., Yang, S., Choi, S. H., Wu, X., Cutmore, L. C., Andrade, J., Huang, L., Amatya, C., Cam, M., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.07.001 · Cited by 22
Neurological adverse effects of chimeric antigen receptor T-cell therapy
Saleki, K., Mohamadi, M. H., Alijanizadeh, P., & Rezaei, N. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2248390 · Cited by 23
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Xiong, Q., Wang, H., Shen, Q., Wang, Y., Yuan, X., Lin, G., & Jiang, P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05101-1 · Cited by 21
Reagan, P. M., & Friedberg, J. W. (2021) · Future Oncology · doi:10.2217/fon-2020-0291 · Cited by 21
Self-citationSequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
Lownik, J. C., Boiarsky, J., Birhiray, R. E., Merchant, A. A., & Mead, M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1962 · Cited by 21
Evolving strategies for addressing CAR T-cell toxicities
Rankin, A. W., Duncan, B. B., Allen, C., Silbert, S. K., & Shah, N. N. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10227-1 · Cited by 22
Ahmed, N., Kambhampati, S., Hamadani, M., Hu, Z., Grover, N. S., Shadman, M. S., Locke, F. L., Gerson, J. N., Frank, M. J., Budde, L. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015014 · Cited by 21
Self-citationEHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
Jerkeman, M., Aurer, I., Campo, E., Cheah, C. Y., Clark, J., Doorduijn, J. K., Eyre, T. A., Fehr, M., Giné, E., da Silva, M. G., et al. (2025) · HemaSphere · doi:10.1002/hem3.70233 · Cited by 24
ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy
Brown, A. R., Jindani, I., Melancon, J., Erfe, R., Westin, J. R., Feng, L., & Gutiérrez, C. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0286le · Cited by 20
Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
Crees, Z. D., & Ghobadi, A. (2021) · Cancers · doi:10.3390/cancers13205181 · Cited by 24
Dong, R., Wang, Y., Lin, Y., Sun, X., Xing, C., Zhang, Y., Wang, H., Dai, L., Kang, Y., & Jiang, S. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3814 · Cited by 20
Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors
Wang, X., Meng, F., Li, X., Xue, L., Chen, A., Qiu, Y., Zhang, Z., Li, L., Liu, F., Li, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202205044 · Cited by 21
Ahmed, N., Wesson, W., Mushtaq, M. U., Porter, D. L., Nasta, S. D., Brower, J., Bachanová, V., Hu, M., Nastoupil, L. J., Oluwole, O. O., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.019 · Cited by 20
Kheyrolahzadeh, K., Tohidkia, M. R., Tarighatnia, A., Shahabi, P., Nader, N. D., & Aghanejad, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121917 · Cited by 20
Saifi, O., Lester, S. C., Breen, W. G., Rule, W. G., Lin, Y., Bennani, N. N., Rosenthal, A. C., Munoz, J. L., Murthy, H. S., Kharfan‐Dabaja, M. A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27155 · Cited by 20
Self-citationAutomating CAR‐T Transfection with Micro and Nano‐Technologies
Hu, T., Kumar, A. R. K., Luo, Y., & Tay, A. K. P. (2023) · Small Methods · doi:10.1002/smtd.202301300 · Cited by 22
Jerkeman, M., Kolstad, A., Hutchings, M., Pasanen, A., Meriranta, L., Niemann, C. U., Jørgensen, R. R. K., El‐Galaly, T. C., Riise, J., Leppä, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011920 · Cited by 20
Advancements in Cell-Based Therapies for HIV Cure
Matsui, Y., & Miura, Y. (2023) · Cells · doi:10.3390/cells13010064 · Cited by 21
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00484-9 · Cited by 20
Self-citationMalinverni, C., Bernardelli, A., Glimelius, I. C., Mirandola, M., Smedby, K. E. E., Tisi, M. C., Giné, E., Albertsson‐Lindblad, A., Marín‐Niebla, A., Rocco, A. D., et al. (2024) · Blood · doi:10.1182/blood.2023023525 · Cited by 20
Tang, J., Chen, J., Lü, X. Q., Cao, H., Ling, Y., Wu, Y., Qian, L., He, Y., Song, B., & Wang, H. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01626 · Cited by 20
Jacobson, C. A., & Maus, M. V. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003391 · Cited by 20
Self-citationIndustrializing engineered autologous T cells as medicines for solid tumours
Britten, C. M., Shalabi, A. M., & Hoos, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00175-8 · Cited by 20
Mohty, R., & Gauthier, J. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01420-9 · Cited by 20
Liang, J., Wang, W., Wang, R., Gao, R., Du, K., Duan, Z., Zhang, X., Li, Y., Wu, J., Yin, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216877 · Cited by 19
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma
López, C., Silkenstedt, E., Dreyling, M. H., & Beà, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011763 · Cited by 23
van Besien, H. J., Easwar, N., Demetres, M. R., Pasciolla, M. S., Shore, T. B., Leonard, J. P., Barker, J. N., Martin, P., & Yamshon, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016291 · Cited by 20
Dholaria, B., Savani, B. N., Huang, X., Nagler, A., Perales, M., & Mohty, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17460 · Cited by 19
Stelmach, R., Berning, P., Niemann, A.-L., Wethmar, K., Bergmann, S., Lutz, M., Schliemann, C., Mesters, R. M., Keßler, T., Schmitz, N., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04650-5 · Cited by 19
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
Polgárová, K., Otáhal, P., Šálek, C., & Pytlík, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.876758 · Cited by 19
He, P., Liu, H., Zimdahl, B., Wang, J., Luo, M., Chang, Q., Tian, F., Fan, N., Yu, D., Liu, H., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04132-9 · Cited by 22
Gong, W., Qiu, Y., Li, M., Chen, L., Li, Y., Yu, J.-Q., Kang, L., Sun, A., Wu, D., Yu, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922212 · Cited by 22
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 19
Mercadal, S., Gómez, C. A., Lee, C. J., & Couriel, D. R. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05131-7 · Cited by 19
Martin, T. G., Madduri, D., Pacaud, L. B., & Usmani, S. Z. (2023) · Future Oncology · doi:10.2217/fon-2022-1317 · Cited by 20
How Can We Engineer CAR T Cells to Overcome Resistance?
Glover, M., Avraamides, S., & Maher, J. F. (2021) · Biologics · doi:10.2147/btt.s252568 · Cited by 19
Tenesaca, S., Vásquez, M., Álvarez, M., Otano, I., Fernández-Sendin, M., Trani, C. A. D., Ardaiz, N., Gomar, C., Bella, Á., Aranda, F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001587 · Cited by 18
Frigault, M. J., Maziarz, R. T., Park, J. H., Lazaryan, A., Shah, N. N., Svoboda, J., Lekakis, L. J., Reshef, R., Phillips, C. L., Burke, L. M., et al. (2025) · Blood · doi:10.1182/blood.2024026586 · Cited by 18
Yegya‐Raman, N., Plastaras, J. P., Wright, C. M., Chelius, M. R., Zhang, S., Baron, J. A., Hubbeling, H., Sim, A. J., Robinson, T. J., Jain, M. D., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015855 · Cited by 18
Self-citationWen, P., Ai, Q., Fan, X., Gu, Z., 陈波, & Qian, H. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218257 · Cited by 20
Schwerdtfeger, M., Benmebarek, M.-R., Endres, S., Subklewe, M. S., Desiderio, V., & Kobold, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00628-2 · Cited by 20
Heslop, H. E., Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Chen, Y., Dezern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.08.016 · Cited by 18
Self-citationYuti, P., Wutti‐in, Y., Sawasdee, N., Kongkhla, K., Phanthaphol, N., Choomee, K., Chieochansin, T., Panya, A., Junking, M., Yenchitsomanus, P., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109442 · Cited by 19
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
Mohty, R., & Kharfan‐Dabaja, M. A. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221142133 · Cited by 18
Hess, L. M., Chen, Y., Abada, P., Koenig, H., & Walgren, R. A. (2022) · Advances in Hematology · doi:10.1155/2022/8262787 · Cited by 18
CAR-T cells for cancer immunotherapy
Xie, Y., Li, X., Wu, J., Zeng, H., Boucetta, H., Wang, B., Yang, P., & He, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108202 · Cited by 18
Localized immunomodulation technologies to enable cellular and organoid transplantation
Nash, A., Lokhorst, N., & Omid Veiseh, A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.008 · Cited by 18
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
Chu, F., Cao, J., Liu, J., Yang, H., Davis, T. J., Kuang, S.-Q., Cheng, X., Zhang, Z., Karri, S., Vien, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007515 · Cited by 18
Kim, S. J., Yoon, S. E., & Kim, W. S. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0388 · Cited by 19
Kitawi, R. C., Ledger, S., Kelleher, A. D., & Ahlenstiel, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052771 · Cited by 18
CAR T-cell expansion: harmful or helpful?
Lionel, A. C., & Neelapu, S. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013146 · Cited by 18
Spiky Gold Nanoparticles, a Nanoscale Approach to Enhanced Ex Vivo T-Cell Activation
Esmaeili, F., Wu, Y. L., Wang, Z., Abdrabou, A., Juska, V. B., Zargartalebi, H., Flynn, C. D., Odom, T. W., Sargent, E. H., & Kelley, S. O. (2024) · ACS Nano · doi:10.1021/acsnano.4c07306 · Cited by 18
Neurotoxicity Biology and Management
Danish, H. H., & Santomasso, B. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000507 · Cited by 18
Toxicities associated with adoptive cellular therapies
Hansen, D. K., Dam, M., & Faramand, R. G. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101287 · Cited by 18
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
Tbakhi, B., & Reagan, P. M. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221080738 · Cited by 18
Self-citationNovel treatments in B cell non-Hodgkin’s lymphomas
Sawalha, Y., & Maddocks, K. J. (2022) · BMJ · doi:10.1136/bmj-2020-063439 · Cited by 19
Marar, R. I., Abbasi, M. A., Prathivadhi-Bhayankaram, S. V., Daryanani, A. E., Villarraga, H. R., Anavekar, N. S., Bhatt, V. R., & Paludo, J. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00713 · Cited by 19
Azcona, M. S. R., Monaco, G., Whitehead, M., Kaufmann, M. M., Alzubi, J., Cathomen, T., & Mussolino, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102618 · Cited by 18
CircRNA: Unlocking new frontiers in therapeutic and vaccine development
Bahrulolum, H., Rouzbahani, F. N., Hoseini, Z. S., Chaharmahali, M., & Hosseini, S. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.038 · Cited by 19
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 17
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14871 · Cited by 21
Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
Zhu, Y., Xiao, B., Zhang, J., Cui, X., Lu, Z., & Wu, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763806 · Cited by 17
Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment
Antoñana-Vildosola, A., Zanetti, S. R., & Palazón, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.004 · Cited by 17
CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
Vu, K., & Frank, M. J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008031 · Cited by 17
Maakaron, J. E., Hu, M., & Jurdi, N. E. (2022) · BMJ · doi:10.1136/bmj-2021-068956 · Cited by 19
Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
Linguanti, F., Abenavoli, E. M., Berti, V., & Lopci, E. (2022) · Cancers · doi:10.3390/cancers14194700 · Cited by 18
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113332 · Cited by 17
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
Albanyan, O., Chávez, J. C., & Munoz, J. L. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221141511 · Cited by 17
Self-citationCytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
Althaus, J., Nilius‐Eliliwi, V., Maghnouj, A., Döring, S., Schroers, R., Hudecek, M., Hahn, S. A., & Mika, T. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03443-1 · Cited by 19
Yang, P., Cai, Q., Zhang, W., Liu, S., Liu, H., Sun, X., Dong, Y., Xiao, X., Wang, J. W., Li, Z., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6009 · Cited by 17
Li, M., Sun, J., & Shi, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1220376 · Cited by 20
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
Lorenzini, T., Cadilha, B. L., Obeck, H., Benmebarek, M.-R., Märkl, F., Michaelides, S., Strzalkowski, T., Briukhovetska, D., Müller, P. J., Nandi, S., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02332-9 · Cited by 17
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma
Nie, E. H., Su, Y., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W., Smith, M. M., Dahiya, S., Han, M. H., Dunn, J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011896 · Cited by 17
Self-citationCesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 20
Badar, T., Johnson, B. D., & Hamadani, M. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01029-4 · Cited by 17
Castellino, A., Tun, A. M., Wang, Y., Habermann, T. M., King, R. L., Ristow, K. M., Cerhan, J. R., Inwards, D. J., Paludo, J., Ansell, S. M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00394-z · Cited by 17
Wang, N., Meng, Y., Wu, Y., He, J., & Liu, F. (2021) · Immunotherapy · doi:10.2217/imt-2020-0221 · Cited by 17
New targets for CAR T therapy in hematologic malignancies
Savani, M., Oluwole, O. O., & Dholaria, B. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101277 · Cited by 17
Advances in Adoptive Cell Therapy for Head and Neck Cancer
Norberg, S. M., & Hinrichs, C. S. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.05.001 · Cited by 18
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
Khurana, A., & Lin, Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00920-6 · Cited by 17
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Chu, Y., Lamb, M. G., Cairo, M. S., & Lee, D. A. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00932-2 · Cited by 17
Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy
McGann, M., Davis, J. A., Gaffney, K. J., Smith, D., Edwards, K. H., Hess, B. T., & Hashmi, H. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.021 · Cited by 17
Gu, Y., Xu, S., Wang, Z., Yang, J., Zheng, S., Wei, Q., Liu, Z., & Xu, X. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.02 · Cited by 17
CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond
Zang, P. D., Angeles, A., & Pal, S. K. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-070623-045906 · Cited by 17
Kim, S. J., Mugundu, G. M., & Singh, A. P. (2024) · Clinical and Translational Science · doi:10.1111/cts.70101 · Cited by 18
Gerber, W. K., Xie, Y., & Patel, S. A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00753 · Cited by 17
Bernard, G., & Evgin, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664403 · Cited by 14
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Park, S., Ho, C. E., Darnell, E. P., Wolff, A. N., Takei, H., Birocchi, F., Bouffard, A. A., Salas‐Benito, D., Escobar, G., Leick, M. B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66102-2 · Cited by 16
Off-the-Shelf Chimeric Antigen Receptor T Cells
Watanabe, N., & Mamonkin, M. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000511 · Cited by 17
Ball, G., Lemieux, C., Cameron, D. A., & Seftel, M. D. (2022) · Current Oncology · doi:10.3390/curroncol29030164 · Cited by 16
Artificial intelligence and chimeric antigen receptor T-cell therapy
Gil, L., & Grajek, M. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0019 · Cited by 16
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
Lv, M., Liu, Y., Liu, W., Xing, Y., & Zhang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.921894 · Cited by 18
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
